Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle of the week is already here, which means there is much to do. No doubt, you can relate on some level. So please join us as we grab a cup of stimulation — remember, no prescription is required — and tackle the Zoom calls and deadlines that are piling up. Meanwhile, here is the latest grab of items of interest to help you along. Hope you conquer the world today, and do stay in touch. …

The Biden administration is working to buy 200 million more doses of Covid-19 vaccines from Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA), a move that could provide enough doses to fully inoculate nearly every American by the end of the summer, NBC News says. The agreement would lessen reliance on getting additional doses from other manufacturers. The Trump administration passed on buying more doses from Pfizer/BioNTech and Moderna and instead bet that additional vaccines from Johnson & Johnson (JNJ) and AstraZeneca (AZN) would come to market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Source: STATNEWS.COM

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]